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Background: Postoperative wound infection is a preventable risk. One potential postoperative complication is
blistering, which leads to increased pain, delayed healing, and higher care costs. The incidence of wound blisters
has been reported to be between 6 and 24%. The aim of this study is to assess whether the risks of postoperative
blistering and wound infections within the first 6 days postsurgery will be reduced using a special dressing
compared to a standard one.
Methods/Design: This is a randomized clinical trial in a University hospital. Patients presenting for knee or hip
arthroplasty or spine procedures will be assessed against study inclusion and exclusion criteria. After giving written
informed consent, patients will be randomized to participate in the 7-day study during hospitalization. One hundred
patients will be randomized per group. The primary outcome measure is blistering incidence from day 0 to day 6
postsurgery. Photo documentation will be evaluated in a blinded manner by the Clinical Evaluation Committee (CEC).
Discussion: A new dressing will be compared to the standard wound dressing regarding the risk of postoperative
blistering, wound infection, and patient comfort. This study will assess the potential advantages of a modern wound
dressing.
Trial registration: ClinicalTrials.gov identifier NCT01988818 (Entered 13 November 2011).
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In view of an increasing elderly population, several au-
thors expect further increases of joint replacement and
spine procedures in western industrialized nations [1-3].
One postoperative complication is wound blistering,
which leads to increased pain, delayed healing, and
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unless otherwise stated.compromised skin integrity. Blistering occurs when the
dermis is separated from the epidermis, and is the in-
variable result of continuous abrasion. The deep, finger-
like projections of epidermal tissue holding the epider-
mis and dermis together are weakened, allowing the two
skin layers to separate. Most blistering occurs on the
fifth or sixth postoperative day [4].
There are several other factors that influence the de-
velopment of blistering. These include the skin changes
generally evident in older patients: that is, there is less
production of collagen (a tough, fibrous protein that
makes skin strong) and elastin (which makes skinl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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with age after the fifth decade [5].
The Incidence of wound blistering has been reported
in the literature to be between 6 and 24% [4,6,7]. Postop-
erative wound complications and surgical site infections
can increase recovery times, inpatient care costs, and
morbidity rates [8].
Mepilex® Border Post-Op is a highly conformable self-
adherent dressing that absorbs blood exudates and
should minimize the risk of maceration. The adhesive
uses SafetacTM technology, a unique and patented
soft silicone adhesive technology that is designed to
minimize pain as well as trauma to the wound and sur-
rounding skin. Mepilex Border Post-Op is CE marked
on the equivalent device Mepilex® Boarder.
In a recent randomized clinical study, three types of
dressings (Mepore Pro, Mepilex Border, and Hypafix
Transparent) were compared in 150 consecutive hip sur-
gery subjects regarding the occurrence of tape blisters.
Blister prevalence was significantly lower for the Mepilex
Border group (3%) than for the Mepore Pro (59%, P
<0.01) and Hypafix group (61%, P <0.01). The mean time
between surgery and blister occurrence and the total
number of dressings used during hospital stay were also
significantly lower for the Mepilex Border group com-
pared to the Mepore Pro and Hypafix groups (P <0.01).
In summary, the dressing with a silicone adhesive (Mepi-
lex Border) significantly reduced the prevalence of blis-
ters following hip surgery [9].
The overall rationale for the current trial is to evaluate
the clinical performance of Mepilex Border Post-Op re-
garding the risks of blistering and maceration as well as
the need for dressing changes, due to its high absorptive
capacity compared to standard wound dressings. In
addition, its performance after spine surgery will be eval-
uated. To our knowledge, it is the first randomized clin-
ical trial with modern wound dressings for spine surgery
at this stage of development.
Objective
The primary objective of this clinical trial is to evaluate
the performance of a self-adhesive absorbent postopera-
tive dressing coated with a soft silicone layer in minimiz-
ing the risk of blistering compared to the hospital
standard dressing (Cosmopor ETM, Fa. Hartmann) after
hip and knee arthroplasty or spinal surgery. The study will
be conducted in a clinical care setting at a University
Hospital. Secondary objectives are to evaluate dressing
performance, comfort, conformability and overall accept-
ability, pain before, during, and after dressing removal,
overall cost regarding dressing wear time, time for dress-
ing changes, and required personnel resources. Wound
blisters will be documented by photographing and count-
ing the number of blisters and its size. The documentationis done by one member of our Clinical Evaluation Com-
mittee (CEC) during the whole period of the study. The
evaluation will be done separately by different members of
our CEC in a blinded manner.
Methods/Design
The study is designed as a randomized trial in a clinical
care setting at a University hospital with two parallel
groups. Patients presenting for knee or hip arthroplasty
or spine surgery will be assessed according to study
inclusion and exclusion criteria. Hip and knee arthro-
plasty are often done in standardized operation proce-
dures. In spine surgery, there is a large variety of
operations. We decide to standardize this by excluding
operations with a hospital stay of fewer than 6 days,
infections, tumor operations or revisions in general.
After written informed consent, the patients will be
randomized to participate in the 7-day study. The
research in this trial will be performed with the approval
of the Ethics Committee of the Medical Faculty of the
University Hospital of Cologne under the reference
number 13-348. The study is performed monocentrally,
so there is no other Ethics Committee involved.
Research carried out in the trial will be in compliance
with the Helsinki Declaration.
Participants and recruitment
Patients aged 18 years or older presenting for hip or
knee arthroplasty or spine surgery and who will stay lon-
ger than 6 days in-house, are eligible for the trial. Pa-
tients whose wounds cannot be appropriately covered
with the dressing will be excluded from this study.
Inclusion criteria are as follow:
1. Age ≥18 years
2. An expected total length of inpatient stay of 6 or
more days
3. Undergoing elective primary arthroplasty of the hip
or knee or spinal surgery
4. Undergoing hip surgery with a standard approach
5. Written informed consent to participate
Exclusion criteria are as follow:
 Sized dressings that are not appropriate for the
incision/wound
 Known allergy/hypersensitivity to any dressing
components
 Polytrauma patients
 Undergoing arthroplasty due to tumor
 Fractures
 Wound at the surgical site prior to surgery
 Neurological deficit of operated side (hemiplegia,
etcetera)
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Intervention
The patients will be randomized 1:1 preoperatively as ei-
ther the Mepilex Border Post-Op group or the standard
dressing group (Figure 1). The Mepilex Border Post-Op
group will get the first dressing removal 6 days after sur-
gery. The standard wound dressing group will receive
dressing removals at day 2, 4 and 6 postsurgery. Both
groups will be visited every day postsurgery to allow
evaluation and documentation of the appearance of the
dressing.
Mepilex Border Post-Op
Patients in this study group will receive postoperative
wound treatment using the Mepilex Border Post-Op
dressing (Mölnlycke, Goteborg, Sweden). This is a self-
adhesive, absorbent dressing designed for acute wounds.
It consists of three main parts. Firstly, there is a flexible
and transparent backing film that is highly vapor perme-
able and waterproof: it is coated with a pressure sensi-
tive water-based acrylic adhesive. Secondly there is aPatients presenting for knee or hip ar
will be assessed according to study inc
Patients will be randomly assigne
treatment groups (allocatio
Mepilex®Border Post-Op (n=100)





-Development of blistering from day 0 to day 6 post surg
Secondary outcome measures:
-Wound complications
-Number of dressing changes
-Number of blisters
-Pain during and after dressing removal
-Performance and acceptability of the dressing
Figure 1 Flow diagram of the progression through the randomized c
absorbent dressing coated with a soft silicone layer compared to a stflexible, absorbent wound pad consisting of two layers:
an absorbent layer with a perforated pattern for good
flexibility, retention, and absorption capacity and a gap
layer for high initial absorption and good distribution of
exudates. Finally, it also includes a wound contact layer
of acrylate adhesive, polyurethane film and soft silicone.
The soft silicone layer adheres gently to dry skin sur-
rounding the wound, but not to the moist wound sur-
face. The soft silicone layer is covered with a
polyethylene release film. The wound coverage section is
white and the adhesive section is transparent to ease
placement.
Standard wound dressing
Patients in this study group will receive postoperative
wound treatment using the standard Cosmopor E adhesive,
an island wound dressing (Hartmann AG, Heidenheim,
Germany).
It is is a sterile, self-adhesive wound dressing made of
soft nonwoven polyester, with an absorbent viscose pad
covered with a nonadherent porous wound contact
layer.throplasty or spine surgery
lusion and exclusion criteria
d to one of the two
n ratio 1:1).
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ective 93/42/EEC for medical devices. The product is
classified as a class I sterile medical device. A conformity
assessment has been performed for Cosmopor E, and it
has been shown to be in compliance with all applicable
requirements of the above mentioned directive.
Outcome measures and assessments
The primary outcome measure is blistering incidence
from day 0 to day 6 postsurgery. Photo documentation
will be evaluated in a blinded manner by the CEC. The
secondary objectives will evaluate the dressing perform-
ance, comfort and overall acceptability by standardized
assessment criteria. The individual pain before, during
and after the dressing removal will be documented in a
1 to 10 rating scale equal to the visual analog scale. Dur-
ing the removal of the dressing, we will count the used
materials and keep records of the time spent in minutes
to summarize the resources and costs in general.
Sample size
Though Pelet et al. [9] reported on a percent blistering
reduction from 59% (Mepore Pro) or even 61% (Hypafix)
to just 3%, we anticipate a less optimistic scenario, for
instance, such as described by Burke et al. [10]. They re-
ported a reduction from 17.7% (standard) to 4.8% (Jubi-
lee), which we consider both realistic and clinically
relevant. To detect this proportional difference with 80%
power and a two-sided type I error of 5%, the uncor-
rected chi-square test requires 93 patients per group.
Accounting for the stratification and any loss to follow-
up (we expect none), 100 patients per group will be
randomized.
Randomization
Patients will be randomly assigned to one of the two treat-
ment groups (allocation ratio 1:1). The randomization will
be stratified according to surgery type (hip, knee, or spine)
and blocked (permuted blocks of varying length). The
randomization will be implemented by sequentially num-
bered, opaque, sealed envelopes containing details of the
dressing to be applied.
Statistical analysis
Primary analysis will be according to the intention-to-
treat. A patient is evaluable for this analysis if they
underwent surgery and received a study treatment. If the
clinical course cannot be fully evaluated, the patient will
be considered a treatment failure. Secondary analysis
will include all patients essentially treated and observed
according to protocol (per protocol set, PPS), that is, no
study visit missed, key outcome variables taken.
Primary outcome analysis: The proportion of incident
blistering in the two groups will be compared with atwo-sided type I error of 5% by the Mantel-Haenszel
test, stratified by type of surgery: that is, the null hypoth-
esis H0: common odds ratio for blistering = 1 is tested
against the alternative hypothesis HA: common odds ra-
tio for blistering ≠ 1. A subgroup analysis by type of sur-
gery and gender will be performed. Heterogeneity of
treatment effect and 95% confidence intervals (odds ra-
tio, relative risk, and risk difference) will be evaluated by
Mantel-Haenszel methods.
Secondary outcome analysis: Pain, number of dressing
changes/blisters, and performance/acceptability ratings
will be analyzed by rank-based methods, that is, Wil-
coxon rank sum/signed rank test. Other wound compli-
cations will be assessed by chi-square test (or Fisher’s
exact test when required).
Discussion
Postoperative wound infection is a preventable risk asso-
ciated with significant adverse outcomes and increased
costs of care. Currently, patients are treated with a
standard dressing, which is changed every 2 days. A
comfortable wound dressing that minimizes the risk of
blistering, which will be changed only after 7 days, once
the wound edges have closed, could minimize the risks
of postoperative superficial wound infections. Because
both treatments are acceptable, we can compare them in
an attempt to optimize postoperative wound care. Fi-
nally, not only the used dressing mentioned in this study
can influence the outcome of developing wound blisters
and complications. Also the number of dressing changes
in general may have a significant influence on the out-
come. This would be considered separately in the final
examination of the study results.
Trial status
At the time of manuscript submission, the trial was actively
enrolling participants.
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